Pharmaceutical Executive-04-01-2012

Issue PDF
Pharmaceutical Executive

April 01, 2012

Come Rain or Shine

Pharmaceutical Executive
Features

April 01, 2012

Throughout her life, HBA Woman of the Year Carolyn Buck-Luce has made progress by recognizing that when one door closes, another one opens.

Pharmaceutical Executive

What does a Scottish vote for independence mean for Big Pharma investment and healthcare funding and delivery in the UK?

Pharmaceutical Executive

India's most prominent scientist, Dr R.A. Mashelkar, President of the Global Research Alliance, on delivering medicines profitably but cheaply to low income countries.

Pharmaceutical Executive
Columns

April 01, 2012

Disclosure rules the day, as industry confronts demands to report supply problems, results of clinical trials, and payment to doctors.

Pharmaceutical Executive
Features

April 01, 2012

This year's Ad Stars embrace creativity through the eyes of the patients. Ben Comer and Jennifer Ringler report.

Pharmaceutical Executive

Phase in of the Sunshine Act will force a reconsideration of the ethical consequences of all types of pharma meetings. How and to what extent remains to be seen.

Pharmaceutical Executive
Columns

April 01, 2012

While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help.

Pharmaceutical Executive
Columns

April 01, 2012

Too often in M&A or product-linked carve-outs, executives overlook the complexities of disentangling operations and the effort required for regulatory re-registration and labeling changes.

Country Report
Pharmaceutical Executive

April 01, 2012

Despite the severe blow to its economy, Ukraine has been recovering at a faster rate than its Western European counterparts

Pharmaceutical Executive
Columns

April 01, 2012

While what is considered 'traditional' marketing has evolved over the years, it's clear that a digital strategy is an absolute necessity to compete today-not just tomorrow.

Pharmaceutical Executive
From the Editor

April 01, 2012

Patents are the chief incentive for drug development. Industry should educate stakeholders about IP protection as a crucial driver of innovation, before it's too late.